慢性阻塞性肺病患者应用氨溴索联合布地奈德及复方异丙托溴铵治疗的临床研究

Clinical study of ambroxol combined with budesonide and compound ipratropium bromide in patients with chronic obstructive pulmonary disease

目的探讨氨溴索联合布地奈德、复方异丙托溴铵雾化治疗慢性阻塞性肺病的临床效果。方法选取2015年3月至2017年3月本院呼吸内科收治的慢阻肺患者98例,根据电脑随机表法分为两组,每组49例。对照组采用常规治疗,观察组采用氨溴索联合布地奈德、复方异丙托溴铵雾化治疗,比较两组动脉血气及肺功能、临床症状消失时间及住院情况。结果治疗前,两组动脉血气及肺功能各项指标比较差异无统计学意义;治疗后,观察组PaO2、FEV1/FVC(%)、FEV1占预计值(%)高于对照组,PaCO2低于对照组,差异具有统计学意义(P<0.05)。观察组喘息缓解、咳嗽消失、哮鸣音消失、湿啰音消失时间均短于对照组,差异具有统计学意义(P<0.05)。观察组每日排痰量多于对照组,但住院天数少于对照组,差异有统计学意义(P<0.05)。结论氨溴索联合布地奈德、复方异丙托溴铵雾化治疗慢阻肺患者可见良好药用,患者动脉血气及肺功能恢复佳。

Objective To compare the clinical study of ambroxol combined with budesonide and compound ipratropium bromide in the treatment of chronic obstructive pulmonary disease. Methods 98 patients with chronic obstructive pulmonary disease were enrolled in the Department of Respiratory Medicine from March 2015 to March 2017, and they were divided into two groups by computer randomization, with 49 cases in each group. The control group received routine treatment, the observation group was treated with ambroxol combined with budesonide and compound ipratropium bromide. The difference of arterial blood gas and lung function, clinical symptoms disappeared and hospitalization were compared between the two groups. Results There was no significant difference in arterial blood gas and lung function between the two groups before treatment. After treatment, PaO2, FEV1/FVC(%) and FEV1 accounted for the predicted value(%) were higher than the control group. PaCO2 was lower than the control group, and the difference was significant(P<0.05). The observation group had wheezing relief, cough disappeared, wheezing sound disappeared, and wet sputum disappeared time was shorter than the control group, the difference was statistically significant(P<0.05). The daily sputum volume of the observation group was higher than that of the control group, but the hospitalization days were less than the control group, and the difference was statistically significant(P<0.05). Conclusion Ambroxol combined with budesonide and compound ipratropium bromide in the treatment of patients with chronic obstructive pulmonary disease can be seen as good medicinal, and the arterial blood gas and lung function recovery is good.